人民财讯8月27日电，百龙创园（605016）8月27日晚间披露半年报，2025年上半年，公司实现营业收入 为6.49亿元，同比增长22.18%；归母净利润1.7亿元，同比增长42%；基本每股收益0.4元。公司拟向全 体股东每10股派发现金红利0.5元(含税)。报告期内，境内外客户需求增长导致公司产品销量增加以及产 品结构调整。 ...

证券代码：605016 证券简称：百龙创园 公告编号：2025-056 山东百龙创园生物科技股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 山东百龙创园生物科技股份有限公司（以下简称"公司"）第四届董事会第 二次会议于 2025 年 8 月 27 日上午 9：00 在公司办公楼一楼第二会议室召开。会 议由董事长窦宝德先生主持，应到董事 7 人，实到董事 7 人，公司董事会秘书及 其他高级管理人员列席本次会议。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，表决形成的决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于 2025 年半年度报告及其摘要的议案》 具体内容详见公司同日在上海证券交易所官方网站及指定媒体上披露的 《2025 年半年度报告》及其《摘要》。 审议结果：表决票 7 票，赞成票 7 票，反对票 0 票，弃权票 0 票。 本议案在提交董事会前已经公司第四届董事会审计委员会 2025 年第二 ...

山东百龙创园生物科技股份有限公司2025 年半年度报告 公司代码：605016 公司简称：百龙创园 山东百龙创园生物科技股份有限公司 2025 年半年度报告 1 / 160 山东百龙创园生物科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人禚洪建、主管会计工作负责人李莉及会计机构负责人（会计主管人员）尚明静 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司 2025 年半年度利润分配方案如下：拟以未来实施本次利润分配方案时股权登记日的总股 本为基数，向全体股东每 10 股派发现金红利人民币 0.5 元（含税）。截至 2025 年 6 月 30 日，公 司总股本为 420,012,320 股，以此为基数测算，合计拟派发现金红利人民币 21,000,616.00 元（含 税），占公司当年归属于上市公司股东的净利润 ...

Group 1 - The company announced the convening of the fourth board meeting on August 27, 2025, to review the proposal for establishing a wholly-owned subsidiary in Jinan [1] - The planned investment is 10 million yuan to set up Baolong Chuangyuan (Jinan) Biotechnology Co., Ltd., with 100% ownership of the registered capital [1] - The purpose of this investment is to strengthen the overseas sales team, actively explore international markets, and enhance the company's revenue and profits in overseas markets [1]

Group 1 - The core viewpoint of the article highlights a significant surge in the sugar substitute concept stocks, with notable performances from several companies [1] Group 2 - Zhonghua International experienced a limit-up increase in its stock price [1] - Baolingbao saw an increase of over 5% in its stock price [1] - Huakang Co., Bailong Chuangyuan, and Xinghuo Technology also experienced upward movements in their stock prices [1]

Group 1 - The concept stocks related to sugar substitutes experienced significant fluctuations, with Zhonghua International hitting the daily limit increase [1] - Baolingbao saw an increase of over 5%, indicating strong market interest [1] - Other companies such as Huakang Co., Bailong Chuangyuan, and Xinghuo Technology also followed suit with upward movements in their stock prices [1]

Company Overview - Shandong Bailong Chuangyuan Biotechnology Co., Ltd. is located in Dezhou (Yucheng) National High-tech Industrial Development Zone, established on December 30, 2005, and listed on April 21, 2021 [1] - The company specializes in prebiotic series products and belongs to the basic chemical industry, specifically chemical products, food, and feed additives [1] Stock Performance - As of August 22, the stock price of Bailong Chuangyuan decreased by 2.02%, trading at 20.85 CNY per share, with a total market capitalization of 8.757 billion CNY [1] - Year-to-date, the stock has increased by 61.73%, with minor fluctuations in the last 5 days (up 0.10%), 20 days (up 0.05%), and 60 days (up 5.96%) [1] Financial Performance - For the period from January to March 2025, Bailong Chuangyuan achieved a revenue of 313 million CNY, representing a year-on-year growth of 24.27% [2] - The company has distributed a total of 162 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [2] Shareholder Information - As of July 31, the number of shareholders increased to 13,300, a rise of 13.13%, while the average circulating shares per person decreased by 11.60% to 31,506 shares [2] - Among the top ten circulating shareholders, Penghua New Emerging Industries Mixed Fund (206009) is the fourth largest, holding 8.6432 million shares, a decrease of 1.1501 million shares from the previous period [2]

Investment Rating - The report provides a standard investment rating for the chemical industry, indicating a positive outlook for specific sectors within the industry [5]. Core Insights - The report highlights the impact of the explosion at Kanto Denka's facility in Japan, which is expected to create opportunities for domestic electronic gas suppliers as Kanto Denka holds a 90% market share in nitrogen trifluoride production in Japan [6][13]. - The first World Humanoid Robot Games held in Beijing is seen as a catalyst for the robotics industry's development, showcasing technological innovation and attracting talent [6][14]. - The report emphasizes the structural optimization of supply in the chemical sector, suggesting a focus on sectors with significant elasticity and competitive advantages, such as organic silicon and membrane materials [6][15]. Industry Performance - The report notes that during the week of August 11 to August 15, 2025, the CSI 300 index rose by 2.37%, while the Shenwan Basic Chemical Index increased by 2.46%, outperforming the market slightly [6][18]. - The top-performing sub-sectors included modified plastics (up 12.29%) and fluorochemicals (up 5.81%), while the worst performers were civil explosives (down 3.02%) and compound fertilizers (down 1.81%) [6][19]. Price Trends - Key products that saw price increases included hydrochloric acid (up 15.38%) and propylene (up 4.00%), while notable declines were observed in butanone (down 7.16%) and liquid ammonia (down 5.89%) [6][26]. - The report tracks price differentials, with significant increases in the propylene-propane differential (up 33.47%) and decreases in the bisphenol A-phenol differential (down 26.57%) [6][28]. Investment Recommendations - The report suggests focusing on sectors that may benefit from supply-side reforms, particularly organic silicon, membrane materials, and dye sectors, with recommended companies including Hoshine Silicon Industry and Zhejiang Longsheng [6][15]. - It also highlights the growing demand for health additives and sugar substitutes driven by new consumer trends, recommending companies that emphasize technological and product differentiation [6][16][17].

证券日报网讯 8月18日晚间，百龙创园发布公告称，公司控股股东窦宝德先生于近日将原质押给中国建 设银行股份有限公司禹城支行的部分股份解除质押，解除质押的股份数为16，224，000股，并办理了股 权解押登记手续。 （文章来源：证券日报） ...

●山东百龙创园生物科技股份有限公司（以下简称"公司"）控股股东窦宝 德先生持有公司股份 198,924,050 股，占公司总股本的比例为 47.36%。本次解 除质押 16,224,000 股后，窦宝德先生持有公司股份累计质押数量为 3,900,000 股，占其持股总数的 1.96%，占公司总股本的 0.93%。控股股东及一致行动人（窦 宝德与窦光朋）合计持有公司股份数量为 209,010,308 股，占公司总股本比例为 公司总股本比例为 2.60%。。 一、本次解除质押的基本情况 窦宝德先生于近日将原质押给中国建设银行股份有限公司禹城支行的部分 股份解除质押，解除质押的股份数为 16,224,000 股，并办理了股权解押登记手 续，现将具体情况公告如下： 股东名称 窦宝德 本次解质股份（股） 16,224,000 占其所持股份比例 8.16% 占公司总股本比例 3.86% 解质时间 2025 年 8 月 15 日 持股数量（股） 198,924,050 持股比例 47.36% 剩余被质押股份数量（股） 3,900,000 剩余被质押股份数量占其所持股份比 例 1.96% 剩余被质押股份数量占公司总股本比 例 ...